Latest:
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Authors
Joseph Gligorov, MD, PhD
Latest:
Novel Treatment Approaches Under Investigation for HER2+ mBC
Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Paolo Strati, MD
Latest:
Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma
Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.
Alberto Montero, MD, MBA, CPHQ
Alberto Montero, MD, MBA, CPHQ, is a clinical director of the Breast Cancer Program at University Hospitals, medical director of the Clinical Trials Unit at Seidman Cancer Center, and professor of Medicine at Case Western Reserve University, all in Cleveland, Ohio.
Latest:
Dr Montero on the Rationale for Evaluating Zanidatamab/Evorpacept in HER2+ Metastatic Breast Cancer
Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.
Adnan F. Danish, MD
Latest:
Dr Danish on Post-CAR T-Cell Bridging Radiation Therapy Eligibility in High-Risk NHL
Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.
Richardo D. Parrondo, MD
Latest:
Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Emma Searle, MD
Latest:
Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma
Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.